HER2-Negative Breast Cancer Completed Phase 1 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01288261Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast CancerTreatment